Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8314607rdf:typepubmed:Citationlld:pubmed
pubmed-article:8314607lifeskim:mentionsumls-concept:C0680272lld:lifeskim
pubmed-article:8314607lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:8314607lifeskim:mentionsumls-concept:C0304227lld:lifeskim
pubmed-article:8314607lifeskim:mentionsumls-concept:C0010186lld:lifeskim
pubmed-article:8314607lifeskim:mentionsumls-concept:C2936280lld:lifeskim
pubmed-article:8314607lifeskim:mentionsumls-concept:C0220812lld:lifeskim
pubmed-article:8314607pubmed:issue2lld:pubmed
pubmed-article:8314607pubmed:dateCreated1993-7-27lld:pubmed
pubmed-article:8314607pubmed:abstractTextRising costs of prescription drugs are a concern to both private and public purchasers. Common methods of controlling or sharing costs include copayments and incentives to use generic substitutes. A study of prescription drug use and costs for a set of employer groups reveals that a common change in the rate of copayment from $3 to $5 per prescription is estimated to be associated with a 5% decrease in the number of prescriptions, an offsetting increase in ingredient costs per prescription, a 10% decrease in employer costs per person, and an increase in employee costs of approximately the $2 copayment per prescription.lld:pubmed
pubmed-article:8314607pubmed:languageenglld:pubmed
pubmed-article:8314607pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8314607pubmed:citationSubsetIMlld:pubmed
pubmed-article:8314607pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8314607pubmed:statusMEDLINElld:pubmed
pubmed-article:8314607pubmed:issn0046-9580lld:pubmed
pubmed-article:8314607pubmed:authorpubmed-author:SmithD GDGlld:pubmed
pubmed-article:8314607pubmed:issnTypePrintlld:pubmed
pubmed-article:8314607pubmed:volume30lld:pubmed
pubmed-article:8314607pubmed:ownerNLMlld:pubmed
pubmed-article:8314607pubmed:authorsCompleteYlld:pubmed
pubmed-article:8314607pubmed:pagination189-98lld:pubmed
pubmed-article:8314607pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:8314607pubmed:meshHeadingpubmed-meshheading:8314607-...lld:pubmed
pubmed-article:8314607pubmed:meshHeadingpubmed-meshheading:8314607-...lld:pubmed
pubmed-article:8314607pubmed:meshHeadingpubmed-meshheading:8314607-...lld:pubmed
pubmed-article:8314607pubmed:meshHeadingpubmed-meshheading:8314607-...lld:pubmed
pubmed-article:8314607pubmed:meshHeadingpubmed-meshheading:8314607-...lld:pubmed
pubmed-article:8314607pubmed:meshHeadingpubmed-meshheading:8314607-...lld:pubmed
pubmed-article:8314607pubmed:meshHeadingpubmed-meshheading:8314607-...lld:pubmed
pubmed-article:8314607pubmed:meshHeadingpubmed-meshheading:8314607-...lld:pubmed
pubmed-article:8314607pubmed:meshHeadingpubmed-meshheading:8314607-...lld:pubmed
pubmed-article:8314607pubmed:meshHeadingpubmed-meshheading:8314607-...lld:pubmed
pubmed-article:8314607pubmed:meshHeadingpubmed-meshheading:8314607-...lld:pubmed
pubmed-article:8314607pubmed:meshHeadingpubmed-meshheading:8314607-...lld:pubmed
pubmed-article:8314607pubmed:meshHeadingpubmed-meshheading:8314607-...lld:pubmed
pubmed-article:8314607pubmed:year1993lld:pubmed
pubmed-article:8314607pubmed:articleTitleThe effects of copayments and generic substitution on the use and costs of prescription drugs.lld:pubmed
pubmed-article:8314607pubmed:affiliationDepartment of Health Services Management and Policy, University of Michigan, Ann Arbor 48109-2029.lld:pubmed
pubmed-article:8314607pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8314607pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8314607lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8314607lld:pubmed